You just read:

Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months

News provided by

Decision Resources Group

Apr 15, 2014, 01:00 ET